Intracoronary or intravenous infusion procedures incur 1–2 days of hospitalisation; chest discomfort and palpitations may be transiently exacerbated. Recovery to baseline functional capacity spans 2–4 weeks. Cardiac imaging baseline is established at 6–12 weeks; clinically meaningful improvement in ejection fraction or symptom scores typically emerges by 3–6 months. Patients continue standard heart-failure pharmacotherapy throughout; no medication reduction is recommended without cardiologist consensus.
Clinical trial data encompasses phase I–II safety documentation and phase II efficacy assessment across >3,000 treated patients globally. Representative studies report left-ventricular ejection fraction (LVEF) improvements of 5–10 percentage points (e.g., 25% → 35%) in 40–55% of treated cohorts over 6–12 months. Cardiac magnetic resonance imaging shows reduction in scar size and infarct zone wall thickness in responders. Exercise tolerance (6-minute walk distance, VO₂ max) improves modestly in 45–50%. Hospitalisation rates for acute decompensation decline by 25–40% in some cohorts over 12-month follow-up. Mortality benefit remains unproven in phase II; pivotal trials are ongoing.
Съм ли кандидат? → · Heart Failure & Cardiac Repair: full overview → · Цена Сърдечна недостатъчност и възстановяване на сърцето → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка